Annual report pursuant to Section 13 and 15(d)

Consolidating Condensed Financial Information of Guarantor Subsidiaries - Consolidating Condensed Statement of Cash Flows (Detail)

v3.8.0.1
Consolidating Condensed Financial Information of Guarantor Subsidiaries - Consolidating Condensed Statement of Cash Flows (Detail) - USD ($)
$ in Thousands
12 Months Ended
Sep. 30, 2017
Sep. 24, 2016
Sep. 26, 2015
Condensed Financial Statements, Captions [Line Items]      
Net cash provided (used) by operating activities $ 114,309 $ 151,426 $ 87,449
Additions to property, plant and equipment (44,659) (27,622) (22,030)
Businesses acquired, net of cash acquired, and investments in joint ventures (103,880) (69,001) (38,384)
Proceeds from asset sales 8,547 3,911 0
Escrow deposit for acquisition-related contingent consideration 6,000    
Change in restricted cash and cash equivalents. (1,735) 2,247 1,126
Investment in equity method investees (12,495) 0 0
Maturities of short term investments 0 0 9,997
Investment in short-term investments 0 0 (17)
Other investing activities (4,355) (730) (546)
Intercompany investing activities 0 0 0
Net cash used in investing activities (164,577) (91,195) (49,854)
Repayments on revolving line of credit (552,000) (419,000) (312,000)
Borrowings on revolving line of credit 552,000 419,000 312,000
Repayments of long-term debt (463) (400,307) (50,289)
Issuance of long-term debt 0 400,000 0
Proceeds from issuance of common stock 0 324 200
Excess tax benefits from stock-based awards 19,946 6,869 2,154
Repurchase of common stock (27,556) (10,873) (18,497)
Payments of contingent consideration (1,300) (2,026) 0
Payment of deferred financing costs 0 (7,560) (258)
Distribution to parent 0 0 0
Distribution to noncontrolling interest (1,019) (592) (1,680)
Intercompany financing activities 0 0 0
Net cash used by financing activities (10,392) (14,165) (68,370)
Effect of exchange rates on cash 75 (668) (317)
Net (decrease) increase in cash and cash equivalents (60,585) 45,398 (31,092)
Cash and cash equivalents at beginning of year 92,982 47,584 78,676
Cash and cash equivalents at end of year 32,397 92,982 47,584
Eliminations      
Condensed Financial Statements, Captions [Line Items]      
Net cash provided (used) by operating activities (4,076) (4,883) (6,719)
Additions to property, plant and equipment 0 0 0
Businesses acquired, net of cash acquired, and investments in joint ventures 0 0 0
Proceeds from asset sales 0 0  
Change in restricted cash and cash equivalents. 0 0 0
Maturities of short term investments     0
Investment in short-term investments     0
Other investing activities 0 0 0
Intercompany investing activities 98,591 129,791 101,752
Net cash used in investing activities 98,591 129,791 101,752
Repayments on revolving line of credit 0 0 0
Borrowings on revolving line of credit 0 0 0
Repayments of long-term debt 0 0 0
Issuance of long-term debt    
Proceeds from issuance of common stock   0 0
Excess tax benefits from stock-based awards 0 0 0
Repurchase of common stock 0 0 0
Payments of contingent consideration 0  
Payment of deferred financing costs   0 0
Distribution to parent 4,076 4,883 6,719
Distribution to noncontrolling interest 0 0 0
Intercompany financing activities (98,591) (129,791) (101,752)
Net cash used by financing activities (94,515) (124,908) (95,033)
Effect of exchange rates on cash 0 0 0
Net (decrease) increase in cash and cash equivalents 0 0 0
Cash and cash equivalents at beginning of year 0 0 0
Cash and cash equivalents at end of year 0 0 0
Parent | Reportable Legal Entities      
Condensed Financial Statements, Captions [Line Items]      
Net cash provided (used) by operating activities (7,418) 3,906 (16,823)
Additions to property, plant and equipment (9,419) (4,513) (2,721)
Businesses acquired, net of cash acquired, and investments in joint ventures (103,880) (69,001) (38,384)
Proceeds from asset sales 229 0  
Escrow deposit for acquisition-related contingent consideration 6,000    
Change in restricted cash and cash equivalents. (1,735) 2,247 1,126
Investment in equity method investees (12,495)    
Maturities of short term investments     9,997
Investment in short-term investments     (17)
Other investing activities (4,355) (730) (546)
Intercompany investing activities (3,828) (83) (15,789)
Net cash used in investing activities (141,483) (72,080) (46,334)
Repayments on revolving line of credit (552,000) (419,000) (312,000)
Borrowings on revolving line of credit 552,000 419,000 312,000
Repayments of long-term debt (89) (400,286) (50,262)
Issuance of long-term debt   400,000  
Proceeds from issuance of common stock   324 200
Excess tax benefits from stock-based awards 19,946 6,869 2,154
Repurchase of common stock (27,556) (10,873) (18,497)
Payments of contingent consideration 0  
Payment of deferred financing costs   (7,560) (258)
Distribution to parent 0 0 0
Distribution to noncontrolling interest 0 0 0
Intercompany financing activities 93,445 127,044 103,326
Net cash used by financing activities 85,746 115,518 36,663
Effect of exchange rates on cash 235 (1,466) (697)
Net (decrease) increase in cash and cash equivalents (62,920) 45,878 (27,191)
Cash and cash equivalents at beginning of year 82,158 36,280 63,471
Cash and cash equivalents at end of year 19,238 82,158 36,280
Non-Guarantor Subsidiaries | Reportable Legal Entities      
Condensed Financial Statements, Captions [Line Items]      
Net cash provided (used) by operating activities 2,846 2,654 7,372
Additions to property, plant and equipment (805) (717) (405)
Businesses acquired, net of cash acquired, and investments in joint ventures 0 0 0
Proceeds from asset sales 0 0  
Change in restricted cash and cash equivalents. 0 0 0
Maturities of short term investments     0
Investment in short-term investments     0
Other investing activities 0 0 0
Intercompany investing activities 0 0 0
Net cash used in investing activities (805) (717) (405)
Repayments on revolving line of credit 0 0 0
Borrowings on revolving line of credit 0 0 0
Repayments of long-term debt 0 0 0
Issuance of long-term debt    
Proceeds from issuance of common stock   0 0
Excess tax benefits from stock-based awards 0 0 0
Repurchase of common stock 0 0 0
Payments of contingent consideration 0  
Payment of deferred financing costs   0 0
Distribution to parent (4,076) (4,883) (6,719)
Distribution to noncontrolling interest (1,019) (592) (1,680)
Intercompany financing activities 5,146 2,747 (1,574)
Net cash used by financing activities 51 (2,728) (9,973)
Effect of exchange rates on cash (94) 464 222
Net (decrease) increase in cash and cash equivalents 1,998 (327) (2,784)
Cash and cash equivalents at beginning of year 9,695 10,022 12,806
Cash and cash equivalents at end of year 11,693 9,695 10,022
Guarantor Subsidiaries | Reportable Legal Entities      
Condensed Financial Statements, Captions [Line Items]      
Net cash provided (used) by operating activities 122,957 149,749 103,619
Additions to property, plant and equipment (34,435) (22,392) (18,904)
Businesses acquired, net of cash acquired, and investments in joint ventures 0 0 0
Proceeds from asset sales 8,318 3,911  
Change in restricted cash and cash equivalents. 0 0 0
Maturities of short term investments     0
Investment in short-term investments     0
Other investing activities 0 0 0
Intercompany investing activities (94,763) (129,708) (85,963)
Net cash used in investing activities (120,880) (148,189) (104,867)
Repayments on revolving line of credit 0 0 0
Borrowings on revolving line of credit 0 0 0
Repayments of long-term debt (374) (21) (27)
Issuance of long-term debt    
Proceeds from issuance of common stock   0 0
Excess tax benefits from stock-based awards 0 0 0
Repurchase of common stock 0 0 0
Payments of contingent consideration (1,300) (2,026)  
Payment of deferred financing costs   0 0
Distribution to parent 0 0 0
Distribution to noncontrolling interest 0 0 0
Intercompany financing activities 0 0 0
Net cash used by financing activities (1,674) (2,047) (27)
Effect of exchange rates on cash (66) 334 158
Net (decrease) increase in cash and cash equivalents 337 (153) (1,117)
Cash and cash equivalents at beginning of year 1,129 1,282 2,399
Cash and cash equivalents at end of year $ 1,466 $ 1,129 $ 1,282